Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
March 30 (Reuters) - A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds.
Read more
(Alliance News) - GlaxoSmithKline PLC said on Friday that the US Food & Drug Administration has amended the emergency use authorization fact sheet for sotrovimab, an investigational Covid-19 neutralizing monoclonal antibody.
Read moreMarch 25 (Reuters) - After producing vaccines and treatments for acute COVID-19 in record time, researchers and drugmakers are turning to finding a cure for long COVID, a more elusive target marked by hundreds of different symptoms afflicting millions of people.
Read moreMarch 24 (Reuters) - London's FTSE 100 ended higher on Thursday, aided by healthcare and consumer staple stocks, although concerns about surging inflation and the fallout from the Ukraine crisis weighed on overall sentiment and dragged down the midcap index.
Read more
(Sharecast News) - Pharmaceutical company GlaxoSmithKline revealed on Thursday that ViiV Healthcare, its HIV venture with Pfizer and Shionogi, has received an approved label update from the Food and Drug Administration for its Cabenuva asset.
Read moreGlaxoSmithKline PLC - Brentford, England-based pharmaceutical firm - GSK Consumer Healthcare Capital entities price a series of fixed-rate senior loan notes as part of their GBP10.00 billion medium term note programme. The UK entity prices GBP300.0 million in notes due 2028 at 2.875% and GBP400.0 million in notes due 2038 at 3.375%. The Dutch entity prices EUR850.0 million in notes due 2026 at 1.250%, EUR750.0 million in notes due 2030 at 1.750%, and EUR750.0 million in notes due 2034 at 2.125%. The US and UK entities price a total of USD8.75 billion in notes due 2024 to 2052 at 3.024% to 4.000%.
Read moreMarch 21 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Read moreMarch 21 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read moreMarch 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.
Read moreMarch 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.
Read moreMarch 17 (Reuters) - Britain's medicines regulator has approved AstraZeneca's antibody-based COVID-19 treatment for preventing infections in adults with poor immune response, marking a major step in the fight against the pandemic as infections surge globally.
Read more(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and Tuesday and not separately reported by Alliance News:
Read moreMarch 11 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Read moreMarch 3 (Reuters) - Western drugmakers and medical device companies warn their plans to keep selling products to Russia may be complicated by economic sanctions targeting the country and its major banks in punishment over Moscow's invasion of Ukraine.
Read more
Last checked at